Dear All: Sweden has been a steady supporter of work on incentives for antibiotics for over a decade – as a reminder, they hosted the 17 Sep 2009 workshop entitled “Innovative Incentives for Effective Antibacterials” that kick-started a conversation between the Swedish and US presidencies that, in turn, generated the momentum that propelled things like
Dear All, If you are a US citizen, you have an opportunity right now (as in today/tomorrow) to push for the inclusion of the DISARM Act in the COVID-19 bill(s) currently being circulated in Congress. As a reminder, DISARM is the legislation that would reimburse QIDP antimicrobials in the hospital setting outside of the DRG
Dear All, I promise that the next email will be all about the 25 Mar 2020 NHS England webinar on their antibiotic evaluation and procurement pilot (you’re going to love it … NICE and NHS England are doing great stuff … go here if you want to see a prior newsletter on this topic), BUT
Dear All, This email was just today received from the team leading the NHS England antibiotic procurement project (go here for a prior newsletter describing the project): Dear Stakeholders, In November 2019, we held a stakeholder webinar to share our response to the comments raised in targeted engagement and to outline proposals for the procurement process.
Dear All (moderately long note alert; be sure to note the new list of funding opportunities just below my signature), FDA have announced a public workshop on 5 Mar 2020 to discuss progress and challenges in the development and advancement of various animal models for serious infection. The Federal Register notice is here and registration is here.
Addendum: This is the first in a 3-newsletters series on this topic. Go here and here for the next two newsletters. Finally, the results of the STRIVE trial have been published as Hassanzadeh et al. in Clinical Infectious Diseases, ciad218, https://doi.org/10.1093/cid/ciad218. Dear All: I just learned that FDA’s Vaccines and Related Biological Products Committee (VRBPAC) will meet at
Addendum: This is the second in a 3-newsletters series on this topic. Go here for the first newsletter and here for the final newsletter. Finally, the results of the STRIVE trial have been published as Hassanzadeh et al. in Clinical Infectious Diseases, ciad218, https://doi.org/10.1093/cid/ciad218. Dear All: I wrote on 19 Oct 2017 about the meeting on 7 Nov 2017
Addendum: This is the third in a 3-newsletters series on this topic. I need to do a specific newsletter on the challenges of vaccines but for now this is the place where I am accumulating relevant papers. Go here and here for the prior newsletters. 5 Feb 2023 addendum: A GSK Staphylococcus aureus vaccine candidate (GSK3878858A) was reported
Addendum: This is the third in a series of newsletters on IM bacitracin. Go here for the prior newsletter and here for the 4th and final newsletter. Aside: I can’t comment on it in detail today, but do note that IACG (Interagency Coordination Group on AMR) have just released their final report to the UN Secretary
Addendum: This is the second in a series of newsletters on IM bacitracin. Go here for the prior newsletter and here for the next newsletter. Dear All: Two somewhat overlapping ideas at the start of the week: First, FDA today announced a funding opportunity and Request for Applications (RFA) for studies that can help target and define durations